A Study of MP-101 in Dementia-Related Psychosis and/or Agitation and Aggression

Summary

A ten-week study to assess MP-101 in Dementia-Related Psychosis and/or Agitation and Aggression

Timeline

Start

2017-05-04

Primary completion

2020-01-30

Completion

2020-01-30

Outcome

Missed primary endpoint

Stopped: “Statistical futility; totality of evidence suggests study unlikely to meet endpoint”

registry analysis (superiority test); Placebo vs MP-101; p = 0.48; Response Ratio 4 (90% CI -18 to 25); Fisher Exact NCT03044249 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	LY2979165	Unknown	60 mg	Oral

Indications